2022
Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter
Anderson G, Bruno-Pacella I. Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter. Psychopharmacology 2022, 240: 1-13. PMID: 36399187, DOI: 10.1007/s00213-022-06276-5.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsSerotonin transporterPlatelet serotonin transporterSERT occupancyReuptake inhibitorsSystematic reviewClinical implicationsPlatelet serotonin contentMeasurement of plateletPlatelet serotonin uptakePractical clinical implicationsStudy of plateletsSerotonin uptakeHealthy controlsSerotonin contentDifferent SSRIsClinical practicePlateletsInhibitorsUptakeSNRIsSSRIsPatientsReviewTransporters
2004
Effects of glucocorticoids on declarative memory function in major depression
Bremner J, Vythilingam M, Vermetten E, Anderson G, Newcomer J, Charney D. Effects of glucocorticoids on declarative memory function in major depression. Biological Psychiatry 2004, 55: 811-815. PMID: 15050862, DOI: 10.1016/j.biopsych.2003.10.020.Peer-Reviewed Original ResearchConceptsMajor depressive disorderDeclarative memory functionVerbal declarative memory functionDay 3Major depressionMemory functionParagraph recallUnipolar major depressive disorderSubset of patientsEffects of glucocorticoidsHealthy human subjectsDepressive disorderTransient impairmentHealthy subjectsRandomized fashionDeclarative memoryGlucocorticoid receptorBrain regionsExogenous cortisolGlucocorticoidsPlaceboDexamethasonePatientsBaselineDepression
1996
Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls
Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, Cohen D. Elevated cerebrospinal fluid corticotropin-releasing ractor in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Biological Psychiatry 1996, 39: 776-783. PMID: 8731518, DOI: 10.1016/0006-3223(95)00221-9.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing factorCSF corticotropin-releasing factorTourette syndromeObsessive-compulsive disorderNormal controlsCerebrospinal fluidPathobiology of TSOCD patientsMedication-free outpatientsCompulsive disorderLumbar cerebrospinal fluidNoradrenergic mechanismsHealthy controlsTS patientsObsessive-compulsive behaviorTic severityCardinal featuresClinical ratingsPatientsSyndromeRelated conditionsStandardized fashionNeurobiological mechanismsGroup differencesDisorders
1995
Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal Fluid Biogenic Amines in Obsessive Compulsive Disorder, Tourette's Syndrome, and Healthy Controls. Neuropsychopharmacology 1995, 12: 73-86. PMID: 7766289, DOI: 10.1038/sj.npp.1380241.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndromeCerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls
Leckman J, Goodman W, Anderson G, Riddle M, Chappell P, McSwiggan-Hardin M, McDougle C, Scahill L, Ort S, Pauls D, Cohen D, Price L. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, tourette's syndrome, and healthy controls. Neuropsychopharmacology 1995, 12: 73-86. DOI: 10.1016/0893-133x(94)00070-g.Peer-Reviewed Original ResearchObsessive-compulsive disorderTourette syndromeHealthy controlsOCD patientsTS patientsHomovanillic acidCerebrospinal fluidCerebrospinal fluid biogenic aminesMedication-free OCD patientsPathobiology of TSCSF HVA levelsCompulsive disorderLumbar cerebrospinal fluidConcentrations of tyrosineHVA levelsCSF norepinephrineNoradrenergic mechanismsSerotonergic mechanismsCSF MHPGSerotonergic systemHealthy subjectsHealthy volunteersNormal volunteersPatientsSyndrome
1994
Elevated Cerebrospinal Fluid Levels of Oxytocin in Obsessive-compulsive Disorder: Comparison With Tourette's Syndrome and Healthy Controls
Leckman J, Goodman W, North W, Chappell P, Price L, Pauls D, Anderson G, Riddle M, McSwiggan-Hardin M, McDougle C, Barr L, Cohen D. Elevated Cerebrospinal Fluid Levels of Oxytocin in Obsessive-compulsive Disorder: Comparison With Tourette's Syndrome and Healthy Controls. JAMA Psychiatry 1994, 51: 782-792. PMID: 7524462, DOI: 10.1001/archpsyc.1994.03950100030003.Peer-Reviewed Original ResearchConceptsCerebrospinal fluid levelsObsessive-compulsive disorderCSF oxytocin levelsTourette syndromeArginine vasopressinFamily historyFluid levelsElevated cerebrospinal fluid levelsTic-related obsessive-compulsive disorderOxytocin levelsSubgroup of patientsSubset of patientsElevated CSF levelsCentral arginine vasopressinSubtype of OCDCSF levelsFamily genetic dataHealthy controlsTic disordersForms of OCDPatientsRelated syndromesCurrent severitySyndromeFamily study dataEnhanced stress responsivity of tourette syndrome patients undergoing lumbar puncture
Chappell P, Riddle M, Anderson G, Scahill L, Hardin M, Walker D, Cohen D, Leckman J. Enhanced stress responsivity of tourette syndrome patients undergoing lumbar puncture. Biological Psychiatry 1994, 36: 35-43. PMID: 8080901, DOI: 10.1016/0006-3223(94)90060-4.Peer-Reviewed Original ResearchConceptsTS patientsLumbar punctureNormal controlsTourette syndromeClinician ratingsEnhanced stress responsivityLumbar puncture stressUrinary norepinephrine excretionTourette syndrome patientsPeak ACTH levelsNorepinephrine excretionACTH levelsSympathetic systemAdrenal axisMedication responsivenessMore norepinephrinePhonic ticsSyndrome patientsUrinary catecholaminesMore ACTHPatientsTic severityNeuropsychiatric disordersSymptom severityStress responsivity
1992
Platelet and whole blood serotonin content in depressed inpatients: Correlations with acute and life-time psychopathology
Mann J, McBride P, Anderson G, Mieczkowski T. Platelet and whole blood serotonin content in depressed inpatients: Correlations with acute and life-time psychopathology. Biological Psychiatry 1992, 32: 243-257. PMID: 1420642, DOI: 10.1016/0006-3223(92)90106-a.Peer-Reviewed Original ResearchConceptsPlatelet serotonin contentBorderline personality disorderBlood serotonin contentSerotonin contentWhole blood serotonin contentSerotonin levelsHealthy controlsPersonality disorderLower platelet serotonin contentComorbid borderline personality disorderHigher serotonin levelsLow serotonin levelsSeverity of depressionPlatelet serotonin levelsLife-time historyBPD attemptersPatient groupMajor depressionPatientsDepressed inpatientsSuicide attemptsSuicidal behaviorNonborderline patientsWhole bloodDisorders
1991
Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment
KING R, RIDDLE M, CHAPPELL P, HARDIN M, ANDERSON G, LOMBROSO P, SCAHILL L. Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment. Journal Of The American Academy Of Child & Adolescent Psychiatry 1991, 30: 179-186. PMID: 2016219, DOI: 10.1097/00004583-199103000-00003.Peer-Reviewed Original ResearchConceptsFluoxetine treatmentObsessive-compulsive disorderUniversity Clinical Research CenterClinical Research CenterMajor risk factorDrug-induced activationPrior suicidal ideationYounger patientsRisk factorsRegulation of aggressionPatientsSuicidal ideationSelf-destructive behaviorFluoxetineAge 10Apparent associationVulnerable individualsDisordersTreatmentIdeationDe novoHospitalizationSymptoms
1988
Tourette's Syndrome: Clinical and Neurochemical Correlates
RIDDLE M, LECKMAN J, ANDERSON G, ORT S, HARDIN M, STEVENSON J, COHEN D. Tourette's Syndrome: Clinical and Neurochemical Correlates. Journal Of The American Academy Of Child & Adolescent Psychiatry 1988, 27: 409-412. PMID: 3182595, DOI: 10.1097/00004583-198807000-00004.Peer-Reviewed Original ResearchConceptsTourette Syndrome Global ScalePHVA levelsTourette syndromeTS patientsLower CSF HVA levelsPlasma homovanillic acid levelsSimple motor ticsHomovanillic acid levelsCSF HVA levelsSignificant inverse correlationHVA levelsMotor restlessnessMotor ticsPretreatment levelsTotal symptomsNeurochemical correlatesTreatment responsePlasma 3Control groupPatientsSyndromeAcid levelsInverse correlationSignificant correlationIndividual items
1987
Parotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation
COHEN D, ORT S, CARUSO K, ANDERSON G, HUNT R, SHAYWITZ B, KREMENITZER M, LECKMAN J. Parotid Gland Salivary Secretion in Tourette's Syndrome and Attention Deficit Disorder: A Model System for the Study of Neurochemical Regulation. Journal Of The American Academy Of Child & Adolescent Psychiatry 1987, 26: 65-68. PMID: 3034852, DOI: 10.1097/00004583-198701000-00013.Peer-Reviewed Original ResearchConceptsAttention deficit disorderTourette syndromeSalivary amylase concentrationTS patientsAmylase concentrationSalivary secretionNeurochemical regulationReceptor functioningTreatment of TSDeficit disorderSalivary amylase secretionParotid gland secretionSingle dosesSalivary volumeClonidinePatientsAmylase secretionSyndromeADD patientsSalivary measuresSecretionTotal amylaseSalivary amylaseDisordersChildren
1986
Rebound Phenomena in Tourette's Syndrome After Abrupt Withdrawal of Clonidine: Behavioral, Cardiovascular, and Neurochemical Effects
Leckman J, Ort S, Caruso K, Anderson G, Riddle M, Cohen D. Rebound Phenomena in Tourette's Syndrome After Abrupt Withdrawal of Clonidine: Behavioral, Cardiovascular, and Neurochemical Effects. JAMA Psychiatry 1986, 43: 1168-1176. PMID: 3465278, DOI: 10.1001/archpsyc.1986.01800120054011.Peer-Reviewed Original ResearchConceptsTourette syndromeNeurochemical effectsAbrupt withdrawalWorsening of ticsClonidine therapyClonidine withdrawalClonidine's effectivenessAdrenergic mechanismsBlood pressureOpen trialTic symptomsUrinary excretionPlasma levelsMotor restlessnessHomovanillic acidClonidine hydrochlorideSyndromeWithdrawal periodPrewithdrawal levelsRebound phenomenonPatientsPulse rateClonidineWithdrawalNorepinephrineBrief debrisoquin administration to assess central dopaminergic function in children
Riddle M, Shaywitz B, Leckman J, Anderson G, Shaywitz S, Hardin M, Ort S, Cohen D. Brief debrisoquin administration to assess central dopaminergic function in children. Life Sciences 1986, 38: 1041-1048. PMID: 3456480, DOI: 10.1016/0024-3205(86)90239-0.Peer-Reviewed Original ResearchConceptsCentral dopaminergic functionDopaminergic functionHomovanillic acid levelsBehavioral side effectsActive antihypertensive agentDebrisoquin sulfatePHVA levelsAntihypertensive agentsSix-hour periodSide effectsBrief administrationNeuropsychiatric disordersAdministration methodsMarked reductionPeripheral techniquesAcid levelsAdministrationPatientsChildrenDebrisoquinPHVA
1984
Whole blood serotonin and tryptophan levels in Tourette's disorder: Effects of acute and chronic clonidine treatment
Leckman J, Anderson G, Cohen D, Ort S, Harcherik D, Hoder E, Shaywitz B. Whole blood serotonin and tryptophan levels in Tourette's disorder: Effects of acute and chronic clonidine treatment. Life Sciences 1984, 35: 2497-2503. PMID: 6595491, DOI: 10.1016/0024-3205(84)90435-1.Peer-Reviewed Original ResearchConceptsChronic clonidine treatmentClonidine treatmentTourette's disorder patientsWhole blood serotoninDisorder patientsTourette's disorderBlood serotoninTryptophan levelsMean differenceChronic treatmentAcute doseNormal controlsMean increaseClonidinePatientsDisordersMode of actionTreatmentSignificant differencesSerotoninBaseline conditionsLevelsDifferencesDoseParotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity
SELINGER D, COHEN D, ORT S, ANDERSON G, CARUSO K, LECKMAN J. Parotid Salivary Response to Clonidine in Tourette's Syndrome: Indicator of Adrenergic Responsivity. Journal Of The American Academy Of Child & Adolescent Psychiatry 1984, 23: 392-398. PMID: 6205037, DOI: 10.1016/s0002-7138(09)60316-2.Peer-Reviewed Original ResearchConceptsDrug-free patientsSalivary volumeTS patientsTourette syndromeSingle doseAdrenergic receptorsLong-term clonidine treatmentAmylase secretionGood therapeutic responseYoung male patientParotid salivary responseAdrenergic responsivityClonidine treatmentSalivary amylase concentrationMale patientsTherapeutic responseNoradrenergic functioningAmylase concentrationPatientsClonidineParotid glandSyndromeSalivary responseT patientsTotal secretion
1981
Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report
Young J, Cohen D, Hattox S, Kavanagh M, Anderson G, Shaywitz B, Maas J. Plasma free MHPG and neuroendocrine responses to challenge doses of clonidine in Tourette's Syndrome: Preliminary report. Life Sciences 1981, 29: 1467-1475. PMID: 6946271, DOI: 10.1016/0024-3205(81)90012-6.Peer-Reviewed Original ResearchConceptsFree MHPGPlasma free MHPGTourette syndromeChallenge doseNeuroendocrine responsesDoses of clonidineSingle oral dosesClonidine administrationResponsive patientsGH responseOral dosesMaintenance treatmentThyroxine indexClonidineTS patientsPatientsMHPGSyndromeT patientsNeuropsychiatric patientsPilot studyPreliminary reportMetabolic responseFurther investigationDose